Drug Trial Radar · NCT06809322
Vorasidenib Maintenance for IDH Mutant Astrocytoma
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
468
Planned (sponsor's estimate)
Start
Jan 16, 2026
Primary completion
Apr 13, 2035
Study completion May 31, 2037
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- Collaborators
- Canadian Cancer Trials Group; Olivia Newton-John Cancer Research Institute
- First posted
- Feb 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main goal of VIGOR is to demonstrate that vorasidenib maintenance therapy improves locally assessed progression-free survival (PFS) from enrolment compared to placebo in patients with IDH-mutant, CNS5 WHO Grade 2 or 3 astrocytoma following the completion of first-line chemoradiotherapy. The primary endpoint is Progression-free survival (PFS), as assessed locally from the date of enrolment using the RANO 2.0 criteria. In this a comparative, randomized (1:1), triple blinded, multicentre phase III superiority trial with one stopping rule for efficacy and futility after end of enrolment, participants in the experimental arm will receive vorasidenib orally once daily at a dose of 40 mg in continuous 28-day cycles while participants in the control arm will receive a matched oral placebo once daily in continuous 28-day cycles
Conditions
- IDH-mutant Grade 2 or 3 Astrocytoma
Interventions
VorasidenibDrug
Vorasidinib will be administered orally once daily at a dose of 40 mg in continuous 28-day cycles
Vorasidenib PlaceboDrug
Matched oral vorasidenib placebo will be administered once daily in continuous 28-day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) by local assessmentTime frame: ~7.7 years and 10.5 years from first patient in
Locations
59 sites in 12 countries. Site status is shown where the registry gives one.
Flinders Medical Centre / Southern Adelaide Local Health Network
Bedford Park, Australia · Not yet recruiting
Chris O'Brien LifeHouse
Camperdown, Australia · Not yet recruiting
Austin Hospital
Heidelberg, Australia · Not yet recruiting
Royal Hobart Hospital
Hobart, Australia · Not yet recruiting
Liverpool Hospital
Liverpool, Australia · Not yet recruiting
Peter MacCallum Cancer Centre
Melbourne, Australia · Not yet recruiting
the Alfred hospital
Melbourne, Australia · Not yet recruiting
Sir Charles Gairdner Hospital
Nedlands, Australia · Not yet recruiting
Royal North Shore Hospital
St Leonards, Australia · Not yet recruiting
Princess Alexandra Hospital
Woolloongabba, Australia · Recruiting
Medical University of Innsbruck
Innsbruck, Austria · Recruiting
Kepler University Hospital - Neuromed campus
Linz, Austria · Recruiting
Medical University of Vienna
Vienna, Austria · Recruiting
Universitair Ziekenhuis Brussel
Brussels, Belgium · Recruiting
Ghent University Hospital
Ghent, Belgium · Recruiting
U.Z. Leuven - Campus Gasthuisberg
Leuven, Belgium · Recruiting
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada · Not yet recruiting
Cross Cancer Institute
Edmonton, Alberta, Canada · Not yet recruiting
BC Cancer Agency - Vancouver
Vancouver, British Columbia, Canada · Not yet recruiting
CancerCare Manitoba
Winnipeg, Manitoba, Canada · Recruiting
QEII Health Sciences Centre Capital District Health Authority
Halifax, Nova Scotia, Canada · Not yet recruiting
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada · Not yet recruiting
Kingston Health Sciences Centre
Kingston, Ontario, Canada · Not yet recruiting
London Health Sciences Centre Research Inc.
London, Ontario, Canada · Not yet recruiting
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada · Not yet recruiting
Odette Cancer Centre Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada · Recruiting
University Health Network Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada · Not yet recruiting
Montreal Neurological Institute and Hospital James Administration Building
Montreal, Quebec, Canada · Not yet recruiting
CIUSSS NIM - Hôpital du Sacré-Cœur de Montréal
Montreal, Quebec, Canada · Not yet recruiting
Hotel-Dieu de Quebec
Québec, Quebec, Canada · Not yet recruiting
CIUSSS de l'Estrie - Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada · Not yet recruiting
Masaryk Memorial Cancer Institute
Brno, Czechia · Recruiting
Universitary hospital Bordeaux France
Bordeaux, France · Recruiting
CHU Lyon - Hopital neurologique Pierre Wertheimer
Lyon, France · Recruiting
Marseille APHM
Marseille, France · Recruiting
Assistance Publique Hopitaux de Paris APHP - Sorbonne
Paris, France · Recruiting
Oncopole Claudius Regaud, IUCT-Oncopole
Toulouse, France · Recruiting
Universitaskliniken Bonn
Bonn, Germany · Recruiting
University Hospital Frankfurt -Senckenberg Institute of Neurooncology
Frankfurt, Germany · Recruiting
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.